Dual Blockade of PKA and NF-κB Inhibits H2 Relaxin-Mediated Castrate-Resistant Growth of Prostate Cancer Sublines and Induces Apoptosis

Hormones and Cancer

Volumn 2, Issue 4, 2011, Pages 224-238

  Vinall, Ruth L ^a   Mahaffey, Christopher M ^a   Davis, Ryan R ^a   Luo, Zunping ^b   Gandour Edwards, Regina ^a   Ghosh, Paramita M ^a   Tepper, Clifford G ^a   de Vere White, Ralph W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Androgen receptor; Castrate resistant prostate cancer; Cyclic AMP; H2 relaxin; NF kappaB; Protein kinase A

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANDROGEN RECEPTOR; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOCETAXEL; H2 RELAXIN; I KAPPA B ALPHA; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEPTIDE HORMONE; PERIFOSINE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL XL; PROTEIN KINASE B; RAPAMYCIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN LNCAP; DNA SEQUENCE; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; UPREGULATION;

APOPTOSIS; CASTRATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; NF-KAPPA B; PROSTATIC NEOPLASMS; RELAXIN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TRANSFECTION;

EID: 79960946507     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-011-0076-4     Document Type: Article

References (49)

1. Arlt A, Schafer H (2002) NFkappaB-dependent chemoresistance in solid tumors. Int J Clin Pharmacol Ther 40(8): 336-347.
2. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP et al (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25(1): 25-29. doi: 10. 1038/75556.
3. Bathgate RA, Samuel CS, Burazin TC, Gundlach AL, Tregear GW (2003) Relaxin: new peptides, receptors and novel actions. Trends Endocrinol Metab 14(5): 207-213.
4. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, Hall KP et al (2008) Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456(7218): 53-59. doi: 10. 1038/nature07517.
5. Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J, Twardowski P, Pan CX et al (2007) The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer 5(7): 433-437.
6. Domingo-Domenech J, Mellado B, Ferrer B, Truan D, Codony-Servat J, Sauleda S, Alcover J et al (2005) Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer 93(11): 1285-1294.
7. Feng S, Agoulnik IU, Bogatcheva NV, Kamat AA, Kwabi-Addo B, Li R, Ayala G, Ittmann MM, Agoulnik AI (2007) Relaxin promotes prostate cancer progression. Clin Cancer Res 13(6): 1695-1702. doi: 10. 1158/1078-0432. CCR-06-2492.
8. Feng S, Agoulnik IU, Li Z, Han HD, Lopez-Berestein G, Sood A, Ittmann MM, Agoulnik AI (2009) Relaxin/RXFP1 signaling in prostate cancer progression. Ann N Y Acad Sci 1160: 379-380. doi: 10. 1111/j. 1749-6632. 2008. 03793. x.
9. Feng S, Agoulnik IU, Truong A, Li Z, Creighton CJ, Kaftanovskaya EM, Pereira R et al (2010) Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer 17(4): 1021-1033. doi: 10. 1677/ERC-10-0073.
10. Figueiredo KA, Palmer JB, Mui AL, Nelson CC, Cox ME (2005) Demonstration of upregulated H2 relaxin mRNA expression during neuroendocrine differentiation of LNCaP prostate cancer cells and production of biologically active mammalian recombinant 6 histidine-tagged H2 relaxin. Ann N Y Acad Sci 1041: 320-327. doi: 10. 1196/annals. 1282. 051.
11. Garcia JA, Danielpour D (2008) Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 7(6): 1347-1354. doi: 10. 1158/1535-7163. MCT-07-2408.
12. Garibay-Tupas JL, Bao S, Kim MT, Tashima LS, Bryant-Greenwood GD (2000) Isolation and analysis of the 3′-untranslated regions of the human relaxin H1 and H2 genes. J Mol Endocrinol 24(2): 241-252.
13. Gittes RF (1991) Carcinoma of the prostate. N Engl J Med 324(4): 236-245. doi: 10. 1056/NEJM199101243240406.
14. Halls ML, Bathgate RA, Roche PJ, Summers RJ (2005) Signaling pathways of the LGR7 and LGR8 receptors determined by reporter genes. Ann N Y Acad Sci 1041: 292-295. doi: 10. 1196/annals. 1282. 043.
15. Hsu SY, Kudo M, Chen T, Nakabayashi K, Bhalla A, van der Spek PJ, van Duin M, Hsueh AJ (2000) The three subfamilies of leucine-rich repeat-containing G protein-coupled receptors (LGR): identification of LGR6 and LGR7 and the signaling mechanism for LGR7. Mol Endocrinol 14(8): 1257-1271.
16. Ivell R, Einspanier A (2002) Relaxin peptides are new global players. Trends Endocrinol Metab 13(8): 343-348.
17. Ivell R, Hunt N, Khan-Dawood F, Dawood MY (1989) Expression of the human relaxin gene in the corpus luteum of the menstrual cycle and in the prostate. Mol Cell Endocrinol 66(2): 251-255.
18. Kasamon KM, Dawson NA (2004) Update on hormone-refractory prostate cancer. Curr Opin Urol 14(3): 185-193.
19. Lessard L, Karakiewicz PI, Bellon-Gagnon P, Alam-Fahmy M, Ismail HA, Mes-Masson AM, Saad F (2006) Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. Clin Cancer Res 12(19): 5741-5745.
20. Levenson RM, Mansfield JR (2006) Multispectral imaging in biology and medicine: slices of life. Cytometry A 69(8): 748-758. doi: 10. 1002/cyto. a. 20319.
21. Liu S, Vinall RL, Tepper C, Shi XB, Xue LR, Ma AH, Wang LY et al (2008) Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway. Oncogene 27(4): 499-505.
22. Marques RB, Erkens-Schulze S, de Ridder CM, Hermans KG, Waltering K, Visakorpi T, Trapman J, Romijn JC, van Weerden WM, Jenster G (2005) Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment. Int J Cancer 117(2): 221-229. doi: 10. 1002/ijc. 21201.
23. McKeithen D, Graham T, Chung LW, and Odero-Marah V Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells. Prostate 70 (9): 982-992 doi: 10. 1002/pros. 21132.
24. Merkle D and Hoffmann R Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: cross-talk with the androgen receptor. Cell Signal 23 (3): 507-515. doi: 10. 1016/j. cellsig. 2010. 08. 017.
25. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B (2008) Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 5(7): 621-628. doi: 10. 1038/nmeth. 1226.
26. Osman I, Dai J, Mikhail M, Navarro D, Taneja SS, Lee P, Christos P, Shen R, Nanus DM (2006) Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression. Cancer 107(11): 2628-2636. doi: 10. 1002/cncr. 22312.
27. Osman I, Yee H, Taneja SS, Levinson B, Zeleniuch-Jacquotte A, Chang C, Nobert C, Nanus DM (2004) Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Clin Cancer Res 10(12 Pt 1): 4096-4100. doi: 10. 1158/1078-0432. CCR-04-0120.
28. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD (1999) Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 18(51): 7389-7394.
29. Perron L, Bairati I, Harel F, Meyer F (2004) Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 15(6): 535-541. doi: 10. 1023/B: CACO. 0000036152. 58271. 5e.
30. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15): 1513-1520.
31. Samuel CS, Tian H, Zhao L, Amento EP (2003) Relaxin is a key mediator of prostate growth and male reproductive tract development. Lab Invest 83(7): 1055-1067.
32. Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D, Fennell DA, Gaudino G, Porta C, Mutti L (2007) Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 13(19): 5942-5951. doi: 10. 1158/1078-0432. CCR-07-0536.
33. Shariff AH, Ather MH (2006) Neuroendocrine differentiation in prostate cancer. Urology 68(1): 2-8. doi: 10. 1016/j. urology. 2006. 02. 002.
34. Shaw EE, Wood P, Kulpa J, Yang FH, Summerlee AJ, Pyle WG (2009) Relaxin alters cardiac myofilament function through a PKC-dependent pathway. Am J Physiol Heart Circ Physiol 297(1): H29-H36. doi: 10. 1152/ajpheart. 00482. 2008.
35. Sherwood OD (2004) Relaxin's physiological roles and other diverse actions. Endocr Rev 25(2): 205-234.
36. Shih VF, Tsui R, Caldwell A and Hoffmann A A single NFkappaB system for both canonical and non-canonical signaling. Cell Res 21 (1): 86-102. doi: 10. 1038/cr. 2010. 161.
37. Silvertown JD, Ng J, Sato T, Summerlee AJ, Medin JA (2006) H2 relaxin overexpression increases in vivo prostate xenograft tumor growth and angiogenesis. Int J Cancer 118(1): 62-73. doi: 10. 1002/ijc. 21288.
38. Silvertown JD, Symes JC, Neschadim A, Nonaka T, Kao JC, Summerlee AJ, Medin JA (2007) Analog of H2 relaxin exhibits antagonistic properties and impairs prostate tumor growth. FASEB J 21(3): 754-765.
39. Singh P, Yam M, Russell PJ, and Khatri A Molecular and traditional chemotherapy: a united front against prostate cancer. Cancer Lett 293 (1): 1-14. doi: 10. 1016/j. canlet. 2009. 11. 019.
40. Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldridge LA, Gardner T, Smith M, Nakshatri H, Cheng L (2004) Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res 10(16): 5501-5507. doi: 10. 1158/1078-0432. CCR-0571-03.
41. Takeshima E, Tomimori K, Kawakami H, Ishikawa C, Sawada S, Tomita M, Senba M et al (2009) NF-kappaB activation by Helicobacter pylori requires Akt-mediated phosphorylation of p65. BMC Microbiol 9: 36. doi: 10. 1186/1471-2180-9-36.
42. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15): 1502-1512.
43. Thompson VC, Hurtado-Coll A, Turbin D, Fazli L, Lehman ML, Gleave ME, Nelson CC (2010) Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancer. Prostate 70(10): 1134-1145. doi: 10. 1002/pros. 21148.
44. Thompson VC, Morris TG, Cochrane DR, Cavanagh J, Wafa LA, Hamilton T, Wang S, Fazli L, Gleave ME, Nelson CC (2006) Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens. Prostate 66(16): 1698-1709.
45. Vinall RL, Hwa K, Ghosh P, Pan CX, Lara PN Jr, de Vere White RW (2007) Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis. Clin Cancer Res 13(20): 6204-6216.
46. Vinall RL, Tepper CG, Shi XB, Xue LA, Gandour-Edwards R, de Vere White RW (2006) The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7. Oncogene 25(14): 2082-2093.
47. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, Ward RL et al (2003) Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A 100(6): 3410-3415.
48. Wu JT, Astill ME, Liu GH, Stephenson RA (1998) Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients. J Clin Lab Anal 12(1): 20-25. doi: 10. 1002/(SICI)1098-2825(1998) 12: 1< 20:: AID-JCLA4> 3. 0. CO; 2-N.
49. Yardy GW, Brewster SF (2005) Wnt signalling and prostate cancer. Prostate Cancer Prostatic Dis 8(2): 119-126. doi: 10. 1038/sj. pcan. 4500794.